Skip to main content

Table 3 Results representing the Cell cycle analysis of MFX and CFX treated Panc-1 cells

From: Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation

24 h Sub G1 G1 S G2 48 h Sub G1 G1 S G2
Panc-1 Panc-1
0 μg/ml 4.8 ± 1.5 61.6 ± 0.5 7.8 ± 0.7 25.8 ± 0.9 0 μg/ml 4.1 ± 0.8 66.2 ± 1 7.3 ± 0.5 22.4 ± 1.5
MFX 100 μg/ml 4.4 ± 1 59.7 ± 2 9.7 ± 1 26.2 ± 2 MFX 100 μg/ml 4 ± 0.5 56.7 ± 2.4 10.8 ± 1.5 28.5 ± 1
MFX 200 μg/ml 5.6 ± 1.2 60.2 ± 1.2 11.6 ± 1.3 22.6 ± 1.4 MFX 200 μg/ml 4.1 ± 1 50.3 ± 3.1 20.6 ± 2 24.6 ± 0.8
MFX 400 μg/ml 10.4 ± 1 % 57.9 ± 2.5 7.1 ± 0.6 24.6 ± 1.5 MFX 400 μg/ml 20.5 ± 2.5 52.8 ± 1.9 12.4 ± 1 14.3 ± 2.2
CFX 100 μg/ml 5.1 ± 0.8 61 ± 1.3 8.4 ± 1 25.5 ± 0.5 CFX 100 μg/ml 4.2 ± 1.1 53.6 ± 1.2 13.4 ± 1.5 28.8 ± 1.7
CFX 200 μg/ml 24 ± 1.2 51 ± 2.1 9 ± 0.5 16 ± 1.6 CFX 200 μg/ml 17.7 ± 2 50.2 ± 2.4 10.6 ± 1.1 21.5 ± 0.9
CFX 400 μg/ml 32 ± 1.5 48.2 ± 3.2 7.3 ± 1 12.5 ± 2 CFX 400 μg/ml 54.4 ± 1.5 28.9 ± 3.3 8.1 ± 0.8 8.6 ± 2.6
  1. Values represent the percent of population in each phase. Values with significant changes have been highlighted with bold format